VANGUARD GROUP INC 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 1:26 pm Unchanged | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | VANGUARD GROUP INC | 8,327,699 3.980% | 0 (Unchanged) | Filing |
| 2024-11-04 10:57 am Sale | 2024-09-30 | 13G | Allogene Therapeutics, Inc. ALLO | VANGUARD GROUP INC | 8,327,699 3.980% | -703,126 (-7.79%) | Filing |
| 2024-02-13 4:59 pm Purchase | 2023-12-29 | 13G | Allogene Therapeutics, Inc. ALLO | VANGUARD GROUP INC | 9,030,825 5.370% | 1,765,604 (+24.30%) | Filing |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Allogene Therapeutics, Inc. ALLO | VANGUARD GROUP INC | 7,265,221 5.040% | 7,265,221 (New Position) | Filing |